Oppenheimer lowered the firm’s price target on Zentalis (ZNTL) to $9 from $10 and keeps an Outperform rating on the shares after quarterly results and catching up with management. The firm believes Azenosertib is a drug that will help people with ovarian cancer. While Oppenheimer acknowledges the company likely won’t have any major clinical milestones, it notes that it should have an important regulatory milestone: FDA buy-in on a confirmatory trial design-which would mean implicit confirmation of azenosertib’s proposed accelerated approval pathway.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZNTL:
- Zentalis Pharmaceuticals: Hold Rating Maintained Amid Lack of Short-Term Catalysts and Stock Decline
- Zentalis Pharmaceuticals: Promising Clinical Trials and Potential for Accelerated Approval Justify Buy Rating
- Zentalis reports Q1 EPS (67c), consensus (61c)
- Zentalis announces first patient dosed in DENALI Part 2 trial of azenosertib
- Zentalis Highlights Azenosertib Findings at 2025 AACR